449 related articles for article (PubMed ID: 31471434)
1. The association between a non-invasive hepatic fibrosis score and urolithiasis among non-alcoholic fatty liver disease (NAFLD) patients in China: a cross-sectional study.
Qin S; Wang J; Zhou C; Zhang Y; Xu Y; Wang X; Wang S
BMJ Open; 2019 Aug; 9(8):e027702. PubMed ID: 31471434
[TBL] [Abstract][Full Text] [Related]
2. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.
Xu HW; Hsu YC; Chang CH; Wei KL; Lin CL
Hepatol Int; 2016 Mar; 10(2):340-6. PubMed ID: 26676626
[TBL] [Abstract][Full Text] [Related]
3. The severity of NAFLD is associated with the risk of urolithiasis.
Qin S; Wang J; Zhou C; Zhang Y; Xu Y; Wang X; Wang S
Br J Biomed Sci; 2019 Apr; 76(2):53-58. PubMed ID: 30430908
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.
Wijarnpreecha K; Thongprayoon C; Scribani M; Ungprasert P; Cheungpasitporn W
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):404-410. PubMed ID: 29215435
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease.
Song DS; Chang UI; Kang SG; Song SW; Yang JM
Gut Liver; 2019 Nov; 13(6):658-668. PubMed ID: 30970434
[TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease.
Nasr P; Hilliges A; Thorelius L; Kechagias S; Ekstedt M
Scand J Gastroenterol; 2016 Sep; 51(9):1126-32. PubMed ID: 27161854
[TBL] [Abstract][Full Text] [Related]
7. Association between serum α-L-fucosidase and non-alcoholic fatty liver disease: Cross-sectional study.
Lu ZY; Cen C; Shao Z; Chen XH; Xu CF; Li YM
World J Gastroenterol; 2016 Feb; 22(5):1884-90. PubMed ID: 26855548
[TBL] [Abstract][Full Text] [Related]
8. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
[TBL] [Abstract][Full Text] [Related]
9. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
11. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
12. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
Jung J; Loomba RR; Imajo K; Madamba E; Gandhi S; Bettencourt R; Singh S; Hernandez C; Valasek MA; Behling C; Richards L; Fowler K; Sirlin CB; Nakajima A; Loomba R
Gut; 2021 Oct; 70(10):1946-1953. PubMed ID: 33214165
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
[TBL] [Abstract][Full Text] [Related]
14. Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.
Zhou YJ; Ye FZ; Li YY; Pan XY; Chen YX; Wu XX; Xiong JJ; Liu WY; Xu SH; Chen YP; Zheng MH
United European Gastroenterol J; 2019 Oct; 7(8):1124-1134. PubMed ID: 31662869
[TBL] [Abstract][Full Text] [Related]
15. Favorable impact of non-alcoholic fatty liver disease on the cerebral white matter hyperintensity in a neurologically healthy population.
Jeong SM; Kwon H; Park S; Yu SJ; Jeong HY; Nam KW; Kwon HM; Park JH
Eur J Neurol; 2019 Dec; 26(12):1471-1478. PubMed ID: 31233672
[TBL] [Abstract][Full Text] [Related]
16. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease.
Peleg N; Issachar A; Sneh-Arbib O; Shlomai A
Dig Liver Dis; 2017 Oct; 49(10):1133-1138. PubMed ID: 28572039
[TBL] [Abstract][Full Text] [Related]
17. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
[TBL] [Abstract][Full Text] [Related]
19. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease.
Dogan S; Celikbilek M; Yilmaz YK; Sarikaya S; Zararsiz G; Serin HI; Borekci E; Akyol L; Pirti I; Davarci SE
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):298-304. PubMed ID: 25629574
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
Younes R; Caviglia GP; Govaere O; Rosso C; Armandi A; Sanavia T; Pennisi G; Liguori A; Francione P; Gallego-Durán R; Ampuero J; Garcia Blanco MJ; Aller R; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; Pareja MJ; Zaki MYW; Grieco A; Fracanzani AL; Valenti L; Miele L; Fariselli P; Petta S; Romero-Gomez M; Anstee QM; Bugianesi E
J Hepatol; 2021 Oct; 75(4):786-794. PubMed ID: 34090928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
